Celltrion announced on the 8th that it has received approval for the Phase III clinical trial plan of Stelara (Ustekinumab)'s biosimilar.

Janssen's autoimmune disease treatment Stelara is a mechanism that inhibits interleukin (IL)-12·23, and has indications for psoriasis, Crohn's disease, and ulcerative colitis. It is known that global sales amount to ₩7 trillion.

Celltrion plans to compare the efficacy, pharmacokinetics, and safety of CT-T43 and Stelara at 7 domestic institutions.

Clinical trials are conducted simultaneously with global trials. Global clinical trials are conducted in Europe and Korea with 446 patients. Global clinical trials have already begun with